Assessing Patient Characteristics That Prolong the Need for Total Hip Arthroplasty Following Surgeon-Administered Intra-articular Corticosteroid Injections

评估外科医生实施关节内皮质类固醇注射后延长全髋关节置换术需求的患者特征

阅读:1

Abstract

PURPOSE OF STUDY: Although intra-articular corticosteroid hip injections may only delay an inevitable surgery, patient-specific factors and individual psychosocial factors that might dissuade immediate surgery are not fully understood. The purpose of this study was to understand the diverse reasons that patients elect to undergo hip injections and the various timelines to total hip arthroplasty (THA). METHODS: A retrospective review was conducted at a single academic medical center identifying all consecutive patients who had undergone fluoroscopically guided intra-articular surgeon-administered corticosteroid hip injections between June 2018 and February 2023. Data collected included baseline demographics, hip radiographic variables, duration of postinjection pain relief, and if THA was performed. Univariate and multivariate logistic regression analyses identified predictors associated with undergoing THA within 6 and 12 months postinjection. RESULTS: A total of 93 patients (22 bilateral) with average age of 59.8 ± 1.6 years and body mass index of 31.0 ± 6.3 kg/m2 were reviewed. Reasons for hip injection included the following: 39% due to fear or anxiety of THA; 33% for diagnostic purposes, primarily to discern if the pain stemmed from another source such as the lumbar spine or knee. Most patients showed advanced osteoarthritis: 44% Kellgren-Lawrence (K-L) grade 3 and 35% K-L grade 4. After injection, the average reported pain relief duration was 3.8 ± 4.9 months. Smoking markedly increased the likelihood of undergoing THA within 6 months (OR = 10.889; P = 0.001) and 12 months (OR = 6.375; P = 0.008). CONCLUSION: This study elucidated the multifaceted reasons patients opt for conservative management through corticosteroid hip injections. The value of patient-centered care is emphasized in managing hip osteoarthritis, as shown in the high patient retention rates postinjection.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。